Development of antiretroviral resistance in children with HIV in low- and middle-income countries

Journal of Infectious Diseases

Volumn 207, Issue SUPPL.2, 2013, Pages

  Fitzgerald, Felicity ^a   Penazzato, Martina ^b   Gibb, Diana ^b  

^a NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

antiretroviral therapy; children; HIV; mother to child transmission; resistance

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE TRANSMISSION; DRUG APPROVAL; DRUG COST; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MIDDLE INCOME GROUP; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOCIAL STATUS; TABLET FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; VERTICAL TRANSMISSION;

ANTIRETROVIRAL THERAPY; CHILDREN; HIV; MOTHER-TO-CHILD TRANSMISSION; RESISTANCE;

ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MUTATION; POVERTY; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84878296267     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit115     Document Type: Article

References (42)

1. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the global AIDS epidemic 2012. Geneva, Switzerland: UNAIDS, 2012.
2. WHO. Antiretroviral therapy for HIV infection in infants and children. Recommendations for a public health approach (2010 version). Geneva, Switzerland: WHO, 2010.
3. Sohn AH, Nuttall JJ, Zhang F. Sequencing of antiretroviral therapy in children in low-and middle-income countries. Curr Opin HIV AIDS 2010; 5:54-60.
4. Cromwell E. DA, Dube Q, Low D, Van Rie A. Barriers to Participation in Early Infant Diagnosis and Treatment of HIV: Malawi. 20th Conference on Retroviruses and Opportunistic Infections. Georgia World Congress Centre, Atlanta, 2013:Paper 914.
5. Castro H, Judd A, Gibb DM, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377:1580-7.
6. Foster C, Judd A, Tookey P, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS 2009; 23:159-66.
7. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis 2011; 11:769-79.
8. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380-9.
9. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to ne-virapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-21.
10. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-20.
11. WHO. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector progress towards Universal Access; WHO, Geneva, Switzerland, 2011.
12. Barker PM, Mphatswe W, Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2011; 56:e45-8.
13. World Health Organization. Programmatic update use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: WHO document production services. Geneva, Switzerland: WHO, 2012.
14. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of anti-retroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-8.
15. Prendergast AJ, Penazzato M, Cotton M, et al. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med 2012; 9:e1001273.
16. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antire-troviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11:273-83.
17. Violari A, Cotton M, Otwombe K, et al. Does early limited ART in infants affect virologic and resistance outcomes? Data from the 6-year CHER trial. In: Program and abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK: HIV11 Congress, 2012.
18. Orrell C. Evolution of resistance in paediatric patients with failure on antiretroviral therapy. In: Program and abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. Glasgow, Uk: HIV11 Congress, 2012.
19. Clinton Health Access Initiative (CHAI) ANTIRETROVIRAL (ARV) CEILING PRICE LIST. Available at: http://www.clintonhealthaccess.org/files/chai-arv- ceilingPriceList-201105-english.pdf. Accessed 7 November 2012.
20. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359:733-40.
21. Nahirya-Ntege P, Musiime V, Naidoo B, et al. Low incidence of abaca-vir hypersensitivity reaction among African children initiating antire-troviral therapy. Pediatr Infect Dis J 2011; 30:535-7.
22. Gibb DM, Walker AS, Kaye S, et al. Evolution of antiretroviral pheno-typic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Antivir Ther 2002; 7:293-303.
23. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012; 12:521-30.
24. Bertagnolio S, De Luca A, Vitoria M, et al. Determinants of HIV drug resistance and public health implications in low-and middle-income countries. Antivir Ther 2012; 17:941-53.
25. Musiime V, Kayiwa J, Kiconco M, et al. Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda. AIDS Res Hum Retroviruses 2012; 28:1647-57.
26. Cotton M. VA, Gibb D, Otwombe K, Josipovic D, Panchia R, Jean-Philippe P, Handelsman E, McIntyre J, Babiker A, and the CHER Team Early ART followed by Interruption Is Safe and Is Associated with Better Outcomes than Deferred ART in HIV+ Infants: Final Results from the 6-Year Randomized CHER Trial, South Africa. 19th Conference on Retroviruses and Opportunistic Infections. Atlanta USA, 2012:Paper 28LB.
27. ARROW. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; In press.
28. Puthanakit T, Jourdain G, Suntarattiwong P, et al. High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther 2012; 9:20.
29. Musiime V, Kaudha E, Kayiwa J, et al. Antiretroviral drug resistance profiles and response to second-line therapy among HIV-1 infected Ugandan children. AIDS Res Hum Retroviruses 2012; 29:449-55.
30. Musiime V, Kasirye P, Naidoo-James B, et al.; ARROW Trial Team. Randomised comparison of once-versus twice-daily abacavir and lami-vudine among 669 HIV+ children in the antiretroviral research for Watoto trial. In: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta: CROI, 2013.
31. Donegan KL, Walker AS, Dunn D, et al. The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther 2012; 17:599-603.
32. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Clin Infect Dis 2010; 51:1081-9.
33. Nahirya-Ntege P, Cook A, Vhembo T, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One 2012; 7:e36186.
34. Kasirye P, Kendall L, Musiime V, et al. Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice-daily as syrups versus scored tablets in HIV-1 infected Ugandan children [poster 1631077]. In: Program and abstracts of the Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, UK: HIV10 Congress, 2010.
35. Arrive E, Dicko F, Amghar H, et al. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One 2012; 7:e33690.
36. Bennett DE, Jordan MR, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis 2012; 54(Suppl 4):S280-9.
37. Abongomera G, Namata H, Nkhata M, et al.; Lablite Project Team. Lablite: baseline mapping survey of decentralised ART service provision in Malawi, Uganda and Zimbabwe [abstract LBPE57]. In: Program and abstracts of the 19th International AIDS Conference. Washington, DC: International AIDS Society, 2012.
38. TApHOD A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. J Int AIDS Soc 2011; 14:7.
39. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011; 56:270-8.
40. Vaz P, Augusto O, Bila D, et al. Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique. Clin Infect Dis 2012; 54(Suppl 4):S369-74.
41. Shet A, Neogi U, Nalini Sahoo P, De Costa A. Effectiveness of first-line highly active antiretroviral therapy among HIV-1-infected children in south India [abstract MOPE044]. In: Program and abstracts of the 19th International AIDS Conference. Washington, DC: International AIDS Society, 2012.
42. Kekitiinwa A, Asiimwe AR, Kasirye P, et al. Prospective long-term outcomes of a cohort of Ugandan children with laboratory monitoring during antiretroviral therapy. Pediatr Infect Dis J 2012; 31:e117-25.